K Dunphy, P Dowling, D Bazou, P O'Gorman - Cancers, 2021 - mdpi.com
Simple Summary This review discusses current techniques used to study post-translational protein modifications (PTMs) and their contribution to blood cancer research. Blood cancer …
L Popović, JP Wintgens, Y Wu, B Brankatschk… - Iscience, 2024 - cell.com
ERBB receptor tyrosine kinases are involved in development and diseases like cancer, cardiovascular, neurodevelopmental, and mental disorders. Although existing drugs target …
M Mahdal, J Neradil, P Mudry, S Paukovcekova… - Cancers, 2021 - mdpi.com
Simple Summary The purpose of this study was to analyze differential cell signaling in response to denosumab treatment to identify and subsequently inhibit molecular targets in …
AJ Bellantoni, LM Wagner - Cancers, 2021 - mdpi.com
Simple Summary Children with metastatic or relapsed solid tumors remain in desperate need of better treatment since conventional chemotherapy is often ineffective and can cause …
M Kyr, P Mudry, K Polaskova, LZ Dubska… - … Journal of Cancer, 2024 - Wiley Online Library
A lot of hope for high‐risk cancers is being pinned on immunotherapy but the evidence in children is lacking due to the rarity and limited efficacy of single‐agent approaches. Here …
Objective MG-63 cells that have osteoblastic and adipogenic differentiation potential were evaluated for internalization, and adipogenic differentiation in the presence and absence of …
P Hu, A Chiarini, J Wu, Z Wei, U Armato, I Dal Prà - Polymers, 2022 - mdpi.com
Background. Our earlier works showed the quick vascularization of mouse skin grafted Bombyx mori 3D silk fibroin nonwoven scaffolds (3D-SFnws) and the release of exosomes …
M Krchniakova, S Paukovcekova, P Chlapek… - Frontiers in …, 2022 - frontiersin.org
Tyrosine kinase inhibitors (TKIs) are frequently used in combined therapy to enhance treatment efficacy and overcome drug resistance. The present study analyzed the effects of …
P Macsek, J Skoda, M Krchniakova, J Neradil… - International Journal of …, 2021 - mdpi.com
Despite constant advances in the field of pediatric oncology, the survival rate of high-risk neuroblastoma patients remains poor. The molecular and genetic features of …